[go: up one dir, main page]

SV2006002258A - Inmunoterapia de trastornos autoinmunes - Google Patents

Inmunoterapia de trastornos autoinmunes

Info

Publication number
SV2006002258A
SV2006002258A SV2005002258A SV2005002258A SV2006002258A SV 2006002258 A SV2006002258 A SV 2006002258A SV 2005002258 A SV2005002258 A SV 2005002258A SV 2005002258 A SV2005002258 A SV 2005002258A SV 2006002258 A SV2006002258 A SV 2006002258A
Authority
SV
El Salvador
Prior art keywords
agents
cell
auto
immunotherapy
diseases
Prior art date
Application number
SV2005002258A
Other languages
English (en)
Inventor
Anand Iyer
Kyriaki Dunussi Joannopoulos
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of SV2006002258A publication Critical patent/SV2006002258A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE DESCRIBEN COMPOSICIONES Y MÉTODOS PARA TRATAR ENFERMEDADES AUTO INMUNES. EN PARTICULAR, SE DESCRIBE EL USO DE AGENTES DE EVACUACIÓN DE LA CÉLULA B Y FUSIONES DE UNA DROGA CITOTÓXICA/AGENTES DE EVACUACIÓN DE LA CÉLULA B CON UNA DROGA DE CARGA SIGNIFICATIVAMENTE MÁS ALTO QUE EN PROCEDIMIENTO REPORTADOS ANTERIORMENTE Y CON AGREGADO MENOR Y UNA FRACCIÓN DE FUSIÓN BAJA (LCF) EN EL TRATAMIENTO DE ENFERMEDADES AUTO INMUNES. TAMBIÉN SE DESCRIBEN TERAPIAS DE COMBINACIÓN Y COMPOSICIONES PARA TRATAR ENFERMEDADES AUTO INMUNES, INCLUYENDO AGENTES DE EVACUACIÓN DE LA CÉLULA B, FUSIONES Y/O AGENTES ANTI-CITOKINES.
SV2005002258A 2004-10-08 2005-10-07 Inmunoterapia de trastornos autoinmunes SV2006002258A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61664704P 2004-10-08 2004-10-08
US68600105P 2005-06-01 2005-06-01

Publications (1)

Publication Number Publication Date
SV2006002258A true SV2006002258A (es) 2006-09-19

Family

ID=36148997

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2005002258A SV2006002258A (es) 2004-10-08 2005-10-07 Inmunoterapia de trastornos autoinmunes

Country Status (13)

Country Link
US (2) US20070264257A1 (es)
EP (1) EP1796735A4 (es)
JP (1) JP2008515926A (es)
AR (1) AR052774A1 (es)
AU (1) AU2005295041A1 (es)
BR (1) BRPI0516531A (es)
CA (1) CA2582919A1 (es)
GT (1) GT200500283A (es)
MX (1) MX2007004049A (es)
PE (1) PE20060972A1 (es)
SV (1) SV2006002258A (es)
TW (1) TW200630106A (es)
WO (1) WO2006042240A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
EP2277532A1 (en) 2002-09-11 2011-01-26 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
JP5055603B2 (ja) 2004-08-04 2012-10-24 メントリック・バイオテック・リミテッド・ライアビリティ・カンパニー 変異Ｆｃ領域
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
KR20080032097A (ko) * 2005-06-20 2008-04-14 메다렉스, 인코포레이티드 씨디19 항체 및 그의 용도
US7956160B2 (en) 2005-07-22 2011-06-07 Amgen Inc. Concentrated protein lyophilates, methods, and uses
CA2893252C (en) 2005-08-24 2018-05-29 Immunogen, Inc. Process for preparing antibody maytansinoid conjugates
RS54163B1 (sr) * 2006-05-30 2015-12-31 Genentech Inc. Anti-cd22 antitela, njihovi imunokonjugati i njihova upotreba
JP2008105953A (ja) * 2006-10-23 2008-05-08 Kyoto Sangyo Univ Ｂ細胞傷害抑制剤
PT2155258T (pt) * 2007-05-22 2017-10-18 Wyeth Llc Processos melhorados para fabricar hidrazidas
EP2167687B1 (en) * 2007-06-08 2013-03-27 Biogen Idec MA Inc. Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
HUE036780T2 (hu) 2008-04-09 2018-07-30 Genentech Inc Új kompozíciók és eljárások immunológiai vonatkozású betegségek kezelésére
AU2009274129B2 (en) * 2008-07-21 2016-02-25 Immunomedics Inc. Structural variants of antibodies for improved therapeutic characteristics
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
KR102444399B1 (ko) * 2009-06-03 2022-09-16 이뮤노젠 아이엔씨 메이탄시노이드의 제조방법
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
JP4495776B1 (ja) 2009-07-30 2010-07-07 日本製薬株式会社 融合蛋白質
KR20130009760A (ko) 2010-02-10 2013-01-23 이뮤노젠 아이엔씨 Ｃｄ２０ 항체 및 이의 용도
CN107537040A (zh) 2011-03-29 2018-01-05 伊缪诺金公司 通过一步法制备类美登素抗体缀合物
MY173865A (en) * 2011-09-22 2020-02-25 Amgen Inc Cd27l antigen binding proteins
SG11201502429YA (en) 2012-10-04 2015-04-29 Immunogen Inc Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
KR20160030936A (ko) 2013-07-16 2016-03-21 제넨테크, 인크. Pd-1 축 결합 길항제 및 tigit 억제제를 사용한 암을 치료하는 방법
KR20170084328A (ko) * 2014-11-21 2017-07-19 엘리 디. 에렌프라이스 모노클로날 항체의 투여를 위한 병용 요법
CN108137691B (zh) 2015-09-02 2021-10-19 耶路撒冷希伯来大学伊萨姆研究发展有限公司 特异性针对人类t-细胞免疫球蛋白和itim结构域(tigit)的抗体
NZ739750A (en) 2015-09-25 2019-11-29 Genentech Inc Anti-tigit antibodies and methods of use
GB201610512D0 (en) * 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
CN115054587B (zh) * 2022-05-12 2023-11-21 山东大学 一种胎盘靶向纳米药物的制备及在妊娠合并自身免疫性疾病治疗中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4286483B2 (ja) * 1999-06-09 2009-07-01 イムノメディクス， インコーポレイテッド Ｂ細胞をターゲットとする抗体を使用する自己免疫疾患に対する免疫療法
CN1646161A (zh) * 2002-02-21 2005-07-27 杜克大学 自身免疫疾病的药剂和治疗方法
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
DK2289936T3 (en) * 2002-12-16 2017-07-31 Genentech Inc IMMUNGLOBULIN VARIATIONS AND APPLICATIONS THEREOF
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins

Also Published As

Publication number Publication date
JP2008515926A (ja) 2008-05-15
TW200630106A (en) 2006-09-01
EP1796735A4 (en) 2007-12-12
US20110027273A1 (en) 2011-02-03
PE20060972A1 (es) 2006-12-03
GT200500283A (es) 2006-05-08
US20070264257A1 (en) 2007-11-15
WO2006042240A2 (en) 2006-04-20
MX2007004049A (es) 2007-05-24
AR052774A1 (es) 2007-04-04
CA2582919A1 (en) 2006-04-20
WO2006042240A3 (en) 2006-09-21
AU2005295041A1 (en) 2006-04-20
BRPI0516531A (pt) 2008-09-09
EP1796735A2 (en) 2007-06-20

Similar Documents

Publication Publication Date Title
SV2006002258A (es) Inmunoterapia de trastornos autoinmunes
UY28287A1 (es) Combinaciones para el tratamiento de enfermedades que impican proliferación, migración o apoptosis celulares de células de mieloma, o angiogénesis
TW200602078A (en) Uses of anti-CTLA-4 antibodies
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
AR053651A1 (es) Tratamiento combinado de anticuerpo antictla4 r inhibidor de aromatasa para el cancer de mama
MX2019010171A (es) Composiciones, articulos de fabricacion y metodos relacionados con la dosificacion en la terapia celular.
DOP2017000177A (es) Nuevos anticuerpos anti-cd38 para el tratamiento del cáncer
EA201300246A1 (ru) Ингибиторы тирозинкиназы брутона
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
PE20050928A1 (es) Combinaciones terapeuticas de anticuerpo anti-igfr1
ATE284698T1 (de) Aktivierung natürlicher killerzellen durch adenosin-a3-rezeptoragonisten
PA8626201A1 (es) Conjugados de caliqueamicina
EP4545143A3 (en) Early intervention methods to prevent or ameliorate toxicity
TW200630093A (en) Dose forms
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
AR061122A1 (es) Regimen de cladribina para tratar la escleorosis multiple
AR039103A1 (es) Uso de inhibidores de il-18 para el tratamiento y/o prevencion de enfermedades vasculares perifericas
AR035293A1 (es) Composicion oftalmica.
DOP2006000013A (es) Dosis de anticuerpos en el tratamiento de enfermedades asociadas a las celulas b
CL2008001104A1 (es) Compuestos derivados de [1,2,3]triazolo[4,5-b]piridin-carboxamidas y [1,2,3]triazolo[4,5-d]pirimidin-carboxamidas, inhibidores de mgl y faah; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento de delolores agudos o cronicos, vertigos, vomitos, nauseas, sindrome metaloico, dispipidemia, entre otros.
MX2007003907A (es) Agentes terapeuticos con toxicidad reducida.
TW200630105A (en) Herbal composition PHY906 and its use in chemotherapy
ECSP10010716A (es) Combinaciones farmaceuticas.
DE602006019977D1 (de) Therapie mit anti-cd4-antikörpern und bestrahlung
AR079000A1 (es) Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas

Legal Events

Date Code Title Description
FD Lapse